Earnings Troubles May Signal Larger Issues for Sunflower Pharmaceutical GroupLtd (SZSE:002737) Shareholders

Last week's earnings announcement from Sunflower Pharmaceutical Group Co.,Ltd (SZSE:002737) was disappointing to investors, with a sluggish profit figure. Our analysis has found some reasons to be concerned, beyond the weak headline numbers.

View our latest analysis for Sunflower Pharmaceutical GroupLtd

The Impact Of Unusual Items On Profit

To properly understand Sunflower Pharmaceutical GroupLtd's profit results, we need to consider the CN¥114m gain attributed to unusual items. While it's always nice to have higher profit, a large contribution from unusual items sometimes dampens our enthusiasm. When we crunched the numbers on thousands of publicly listed companies, we found that a boost from unusual items in a given year is often not repeated the next year. And that's as you'd expect, given these boosts are described as 'unusual'. Assuming those unusual items don't show up again in the current year, we'd thus expect profit to be weaker next year (in the absence of business growth, that is).

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Sunflower Pharmaceutical GroupLtd.

Our Take On Sunflower Pharmaceutical GroupLtd's Profit Performance

Arguably, Sunflower Pharmaceutical GroupLtd's statutory earnings have been distorted by unusual items boosting profit. Therefore, it seems possible to us that Sunflower Pharmaceutical GroupLtd's true underlying earnings power is actually less than its statutory profit. Nonetheless, it's still worth noting that its earnings per share have grown at 48% over the last three years. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. Keep in mind, when it comes to analysing a stock it's worth noting the risks involved. For example - Sunflower Pharmaceutical GroupLtd has 1 warning sign we think you should be aware of.

This note has only looked at a single factor that sheds light on the nature of Sunflower Pharmaceutical GroupLtd's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying to be useful.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.